Legend Biotech (LEGN) is facing turbulence following the resignation of CEO Ying Huang, which has sparked investor concerns, leading to a 34% drop in share price over the past month and a 51% decline over the past year. Alan Bash, the head of CARVYKTI, has been appointed as Interim CEO. Despite holding a prominent CAR T therapy and generating $1.14 billion in revenue, the company is seen as undervalued at around $19.05 per share compared to a fair value of $54.23. While the future holds potential through ongoing trials and expanding markets, investors are cautious due to ongoing losses and reliance on a single product.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s
